

AUG. 1 1 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 148 RTB

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

6

1

| Complete if Known | |
|------------------------|-------------------------------|
| Application Number | 09/891,138 |
| Filing Date | June 25, 2001 |
| First Named Inventor | Lin, Daniel Chi-Hong, et. al. |
| Art Unit | 1647 |
| Examiner Name | Christopher J. Nichols |
| Attorney Docket Number | 018781-006210US |

*RECEIVED
AUG 6 2003
TECH CENTER 1600
1600/2900*

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T- <input type="checkbox"/> |
|--------------------|-----------------------|---------------------------|---|--------------------------------|--|---|--------------------------------|
| | | Country Code ³ | Number ⁴ Kind Code ⁵ (# known) | | | | |
| CSJ | CB | PCT | WO 01/79449 | A2 | 10/25/2001 | Hyseq, Inc. | <input type="checkbox"/> |
| | CC | PCT | WO 01/90304 | A2 | 11/29/2001 | Human Genome Sciences, Inc. | <input type="checkbox"/> |
| | CD | PCT | WO 01/98351 | A2 | 12/27/2001 | Incyte Genomics, Inc. | <input type="checkbox"/> |
| ↓ | CE | PCT | WO 02/61087 | A2 | 08/08/2002 | Lifespan Biosciences, Inc. | <input type="checkbox"/> |
| CSJ | CF | PCT | WO 03/000893 | A2 | 01/03/2003 | Decode Genetics EHF. | <input type="checkbox"/> |
| | | | | | | | <input type="checkbox"/> |
| | | | | | | | <input type="checkbox"/> |
| | | | | | | | <input type="checkbox"/> |

| | | | |
|-----------------------|---|--------------------|-----------|
| Examiner Signature |  | Date Considered | 2/11/2004 |
|-----------------------|---|--------------------|-----------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (**optional**). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED


OCT 01 2002

PTO/SB/08B (10-01)

TECH CENTER 1600/1600

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



1

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | Complete if Known | | | |
|--|--|------------------------|-------------------------------|--|--|
| | | Application Number | 09/891,138 | | |
| | | Filing Date | June 25, 2001 | | |
| | | First Named Inventor | Lin, Daniel Chi-Hong, et. al. | | |
| | | Art Unit | 1646 1647 | | |
| | | Examiner Name | Not yet assigned - NICHOLS | | |
| | | Attorney Docket Number | 018781-006210US | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|--------------------|-----------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|---|--|--------------------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| CGN | BA | EP | 1 096 009 | A1 | 05/02/2001 | Pfizer Limited et al. | <input type="checkbox"/> | <input type="checkbox"/> |
| | BB | WO | 00/22131 | A2 | 04/20/2000 | Dominic P. Behan et al. | <input type="checkbox"/> | <input type="checkbox"/> |
| | BC | WO | 00/31258 | A2 | 06/02/2000 | Ruoping Chen et al. | <input type="checkbox"/> | <input type="checkbox"/> |
| | BD | WO | 01/25432 | A2 | 04/12/2001 | Schering Corporation | <input type="checkbox"/> | <input type="checkbox"/> |
| | BE | WO | 01/33221 | A1 | 05/10/2001 | SmithKline Beecham Corporation et al | <input type="checkbox"/> | <input type="checkbox"/> |
| | BF | WO | 01/46414 | A1 | 06/28/2001 | Banyu Pharmaceutical CO., LTD. | <input type="checkbox"/> | <input type="checkbox"/> |
| | BG | WO | 01/85793 | A2 | 11/15/2001 | Pharmacia & Upjohn Company | <input type="checkbox"/> | <input type="checkbox"/> |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| CGN | BH | STADEL J. et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol. 18, no. 11, pp. 430-437, (November 1, 1997) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
Signature*Julia*Date
Considered

4/8/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1388300 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

OCT 09 2001

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

4
Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

09/891,138

Filing Date

June 25, 2001

First Named Inventor

Lin, Daniel Chi-Hong

Group Art Unit

1640 1645

Examiner Name

Nichols

Attorney Docket Number

018781-006210USC

*RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
OCT 10 2001*

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| CGD | AA | US 5,871,963 | A | Conley, et al. | 02-16-1999 |
| CGD | AB | US 5,955,309 | A | Ellis, et al. | 09-21-1999 |
| CGD | AC | US 6,063,582 | A | Conley, et al. | 05-16-2000 |
| CGD | AD | US 6,204,017 | B1 | Behan, et al. | 03-20-2001 |
| CGD | AE | US 6,222,029 | B1 | Edwards, et al. | 04-24-2001 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | |
| CGD | AF | EPO | WO 96/05302 | A1 | Takeda Chemical Industries, LTD. | 02-22-1996 |
| | AG | EPO | WO 97/24929 | A1 | Human Genome Sciences, Inc. | 07-17-1997 |
| | AH | EPO | WO 99/06552 | A2 | Genset | 02-11-1999 |
| | AI | EPO | WO 00/11166 | A1 | Millennium Pharmaceuticals, Inc. | 03-02-2000 |
| | AJ | EPO | WO 00/22131 | A2 | Behan, et al. | 04-20-2000 |
| | AK | EPO | WO 00/28032 | A2 | Incyte Pharmaceuticals, Inc. | 05-18-2000 |
| | AL | EPO | WO 00/61628 | A1 | Human Genome Sciences, Inc. | 10-19-2000 |
| | AM | EPO | WO 01/31014 | A2 | Pharmacia & Upjohn Company | 05-03-2001 |
| | AN | EPO | WO 00/31258 | A2 | Arena Pharmaceuticals, Inc. | 06-02-2000 |
| ↓ | AO | EPO | WO 01/36473 | A2 | Pharmacia & Upjohn Company | 05-25-2001 |
| CGD | AP | EPO | EP 1090925 | A1 | Pfizer Limited | 04-11-2001 |

Examiner Signature

J. Miles

Date Considered

4/8/2003


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1277930 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

PATENT TRADEMARK

| Complete If Known | |
|------------------------|----------------------|
| Application Number | 09/891,138 |
| Filing Date | June 25, 2001 |
| First Named Inventor | Lin, Daniel Chi-Hong |
| Group Art Unit | 4040 1617 |
| Examiner Name | NICHOLS |
| Attorney Docket Number | 018781-006210US |

TECH CENTER 1600/2000
RECEIVED
OCT 12 2001

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|--|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| CGD | AQ | EPO | EP 1096009 | A1 | Pfizer Limited | 05-02-2001 | _____ | _____ |
| | AR | EPO | EP 0892051 | A2 | Smithkline Beecham Corporation | 01-20-1999 | _____ | _____ |
| | AS | EPO | EP 0892051 | A3 | Smithkline Beecham Corporation | 01-20-1999 | _____ | _____ |
| ↓ | AT | JPO | 08-245697 | | Takeda Chemical Industries, LTD. | 09-24-1996 | _____ | _____ |
| CGD | AU | JPO | 11032770 | A | Asahi Kasei Kogyo KK | 07-24-1997 | _____ | _____ |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Examiner Signature

Date Considered

4/8/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
SF 1277930 v1